INTERVIEW

Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research

August 18, 2016
As Japanese drug makers see it increasingly difficult to count on their off-patent brands, mid-sized players are readopting the business model of making profits while their drugs are on patent. Many firms seem to be in-licensing drug candidates as a…

To read the full story

Related Article

INTERVIEW

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…